Eli Lilly’s Zepbound Injection Pen Receives FDA Approval for Treating Obesity and Sleep-Related Breathing Disorder

The Food and Drug Administration has approved Eli Lilly’s blockbuster weight loss drug Zepbound for treating patients with moderate-to-severe obstructive sleep apnea (OSA), expanding its use and possibly its insurance coverage in the U.S.

About OSA

OSA is a sleep-related breathing disorder that occurs when the airways become narrowed or blocked, disrupting breathing during sleep. It is a common condition, affecting an estimated 80 million people in the U.S. Approximately 20 million people have moderate-to-severe OSA, but 85% of cases go undiagnosed.

Zepbound’s Approval

Zepbound is now the first drug treatment option cleared for patients with obesity and moderate-to-severe OSA. The weekly injection is designed to be used in combination with a reduced-calorie diet and increased physical activity. The FDA’s approval is a significant development, as OSA is a serious condition that can lead to complications such as stroke and heart failure if left untreated.

Eli Lilly released initial results from two clinical trials in April, which showed that Zepbound was more effective than a placebo at reducing the severity of OSA in patients with obesity after a year. The company released additional data in June, showing that Zepbound helped resolve OSA in almost half of patients.

The FDA’s approval of Zepbound is a significant step forward in the treatment of OSA, providing a new option for patients who have limited treatment choices. The approval could also pave the way for Eli Lilly to gain broader insurance coverage for the drug. With its effectiveness in resolving OSA in almost half of patients, Zepbound has the potential to make a significant impact on the lives of those affected by this condition.

Q: What is obstructive sleep apnea (OSA)?

A: OSA is a sleep-related breathing disorder that occurs when the airways become narrowed or blocked, disrupting breathing during sleep.

Q: What is Zepbound used for?

A: Zepbound is used to treat patients with obesity and moderate-to-severe OSA, in combination with a reduced-calorie diet and increased physical activity.

Q: Is Zepbound covered by insurance?

A: The approval could pave the way for Eli Lilly to gain broader insurance coverage for Zepbound, but this is still uncertain.

Q: Is there a cure for OSA?

A: There is no cure for OSA, but treatment options such as Zepbound and continuous positive airway pressure (CPAP) therapy can help manage the condition.